Answers are grounded in this paper and cite their sources.
Evaluates genomic co-alterations in early-stage EGFR-mutated NSCLC, suggesting prognostic relevance for treatment planning.
8035 Background: Adjuvant osimertinib is the standard of care for resected stage IB–IIIA EGFR-mutated non-small cell lung cancer (NSCLC), and its benefit in stage IA2–IA3 disease is being evaluated in ADAURA2. However, the prognostic impact of genomic co-alterations, particularly TP53, in early-stage EGFR-mutated NSCLC remains unclear. This study characterized genomic co-alterations and their association with clinicopathologic features in resected early-stage EGFR-mutated NSCLC. Methods: LC-SCRUM-Advantage is a prospective genomic screening program for resected NSCLC. Postoperative tumor specimens were analyzed using the Oncomine Precision Assay to identify co-alterations, including TP53 and other recurrent genes, across major EGFR mutation subtypes. PD-L1 expression was assessed by immunohistochemistry. Clinico-genomic characteristics and survival outcomes were evaluated. Results: Among 1052 enrolled patients, 327 had EGFR-mutated adenocarcinoma (19del 42%, L858R 47%, others 11%). Among tumors with common EGFR mutations, single EGFR alterations accounted for 59%, while co-alterations were detected in 41%. Frequent co-alterations included TP53 (19%), CTNNB1 (4%), PIK3CA (4%), additional EGFR mutations (5%), and EGFR amplification (12%). Co-alteration prevalence increased with pathological stage (IA1 25%, IA2–IA3 41%, IB 53%, II 47%, III 46%), with TP53 showing a similar pattern (IA1 8%, IA2–IA3 18%, IB 19%, II 28%, III 27%). PD-L1 positivity also increased progressively with disease stage (I 37%, II 52%, III 73%; p = 0.0002). TP53-mutated tumors showed a significantly higher PD-L1 positivity rate than TP53 wild-type tumors (60% vs. 39%; p = 0.007). Co-alteration frequencies were comparable across EGFR subtypes. With limited follow-up, five recurrences were observed (IB 1, IIA 1, IIIA 2, IVA 1); three involved co-alterations (TP53, EGFR amplification, EGFR E709V). Conclusions: Genomic co-alterations, including TP53, were common and increased with pathological stage in early-stage EGFR-mutated NSCLC. Co-altered tumors exhibited features associated with aggressive biology, including higher PD-L1 expression. Early recurrences were frequently observed in patients with co-alterations, underscoring their potential prognostic relevance. These findings highlight substantial molecular heterogeneity within early-stage EGFR-mutated NSCLC and support incorporating co-alteration status into risk stratification and adjuvant treatment planning. Ongoing follow-up from this study will further clarify the prognostic and predictive significance of co-alterations, particularly regarding their implications for adjuvant targeted therapy.
No takes yet. Share an insight, caveat, or question.
Yoh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: